ADVERTISING claims by AFT Pharmaceuticals about its Maxigesic paracetamol/ibuprofen combination medication have been found to be "false and misleading" in a Federal Court action brought by Reckitt Benckiser (RB), maker of rival product Nuromol.
RB hailed the decision, saying it "confirms there was no adequate foundation in science for the claims made by the makers of Maxigesic of superiority over any other paracetamol/ibuprofen combination or either paracetamol or ibuprofen alone".
AFT Pharmaceuticals had filed a cross-claim against RB, also claiming that advertising of Nuromol was misleading under the Australian Consumer Law.
The judge also found there was no adequate foundation for claims by Reckitt Benckiser of the superiority of Nuromol because none of the studies cited in the case related to direct comparisons of the products.
A spokesperson for RB said the Federal Court ruling "upholds the community's expectation of the communication of fair, accurate and balanced information about over-the-counter medicines in Australia".
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Oct 18
